BNTX | tickerfilter.com

Fundamental analysis

21%

Profitability 32%

Dept financing 4%

Liquidity 75%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-9.55%

1 Month

-12.07%

3 Months

-18.48%

6 Months

-6.30%

1 Year

2.78%

2 Year

-24.18%

Key data

Stock price

$98.39

P/E Ratio

-40.47

DAY RANGE

$98.25 - $104.76

EPS

-$0.45

52 WEEK RANGE

$76.53 - $131.49

52 WEEK CHANGE

$4.73

MARKET CAP

20.976 B

YIELD

N/A

SHARES OUTSTANDING

237.766 M

DIVIDEND

$2.1322

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.04

PUBLIC FLOAT

AVERAGE 10 VOLUME

$969,490

AVERAGE 30 VOLUME

$856,400

Company detail

CEO: Ugur Sahin
Region: US
Website: biontech.de
Employees: 3,080
IPO year: 2019

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma. It also develops neoantigen specific immunotherapy, such as Autogene cevumeran (BNT122) and BNT141.

BNTX - BioNTech SE